Clinical Trials Logo

Nonalcoholic Fatty Liver Disease clinical trials

View clinical trials related to Nonalcoholic Fatty Liver Disease.

Filter by:

NCT ID: NCT01006889 Completed - Clinical trials for Type 2 Diabetes Mellitus

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Start date: January 2008
Phase: Phase 4
Study type: Interventional

The primary aim of the study is to determine the impact on hepatic steatosis of replacing premeal rapid-acting insulin for exenatide (Byetta) while maintaining bedtime long-acting detemir (Levemir) insulin in well-controlled patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Secondary aims are to learn: 1) the efficacy and safety of such approach and whether it is an acceptable treatment strategy compared to intensified insulin therapy alone; 2) mechanisms of action (i.e., effects on insulin secretion and insulin action); 3) its impact on weight (i.e., can it prevent insulin-associated weight gain or cause weight loss) and rates of hypoglycemia; 4) if it may improve specific plasma biomarkers of disease activity in NAFLD and inflammatory markers common to both conditions - T2DM and NAFLD (i.e., hsCRP, ICAM, VCAM, etc.).

NCT ID: NCT00994682 Completed - Clinical trials for Type 2 Diabetes Mellitus

University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)

Start date: December 2008
Phase: Phase 4
Study type: Interventional

Obesity and Type 2 diabetes are creating a silent epidemic, Non-alcoholic fatty liver disease, which is a chronic liver disease associated with insulin resistance, impaired glucose intolerance, and hepatic fat accumulation. The thiazolidinedione pioglitazone improves glucose/lipid metabolism and histology in NASH by improving insulin resistance in the liver/peripheral/adipose tissues and reducing subclinical inflammation. The aim of this study is to assess the underlying mechanisms at the clinical and molecular level and the long-term efficacy and safety of pioglitazone in NASH in a multiethnic cohort of subjects (predominantly Hispanics, Caucasians and African-Americans - the most common ethnic groups locally) and examine the response including patients with normal glucose tolerance, impaired glucose tolerance or established type 2 diabetes mellitus (T2DM).

NCT ID: NCT00930384 Completed - Psoriasis Clinical Trials

A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis

Start date: November 2009
Phase: N/A
Study type: Observational

Main objectives 1. Establish the association of psoriasis and the presence of NAFLD in the patients with psoriasis attending dermatologic clinic center. Secondary objective 1. Evaluate for the presence of other components metabolic syndrome in this group of patients including hypercholesterolemia, hypertension, obesity, and insulin resistance 2. Determine if there is an association between the extent and severity of psoriasis and the presence of NAFLD. 3. Identify an association between BMI and presence of NAFLD in people with psoriasis and use it as a predictive index for primary screening of NAFLD in psoriatic patients.

NCT ID: NCT00885313 Completed - Obesity Clinical Trials

Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)

EDACN
Start date: March 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA) in children or adolescents with well-characterized and liver biopsy confirmed nonalcoholic fatty liver disease (NAFLD).

NCT ID: NCT00870012 Completed - Clinical trials for Nonalcoholic Fatty Liver Disease

Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics

Start date: February 2009
Phase: N/A
Study type: Interventional

The investigators' aim is to determine whether probiotic and prebiotic treatment plus lifestyle advice is more effective in reducing hepatic fat content than lifestyle advice alone in patients with Nonalcoholic Fatty Liver Disease (NAFLD).

NCT ID: NCT00868933 Completed - Clinical trials for Nonalcoholic Fatty Liver Disease

Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease

Start date: February 2009
Phase: N/A
Study type: Interventional

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in affluent countries. It may progress to cirrhosis and liver cancer. At present, there is no approved drug for NAFLD. Although healthy diet and exercise is often recommended, there is little supportive evidence. Therefore, the investigators plan to conduct a randomized controlled trial comparing a low glycemic index dietary intervention program and simple lifestyle advice in NAFLD patients. The primary endpoint is resolution of NAFLD. Non-invasive tests will be used to assess the study subjects. Proton-magnetic resonance spectroscopy is used to quantify hepatic triglyceride content, and transient elastography is used to quantify liver fibrosis.

NCT ID: NCT00650546 Completed - Clinical trials for Nonalcoholic Fatty Liver Disease

Role of Exenatide in NASH-a Pilot Study

NAFLD
Start date: August 2006
Phase: Phase 2/Phase 3
Study type: Interventional

We hypothesize that exenatide (Byetta), a GLP-1 agonist administered subcutaneously for 24-28 weeks improves liver histology in diabetic patients with biopsy-proven NASH.

NCT ID: NCT00633282 Completed - Clinical trials for Nonalcoholic Fatty Liver Disease

Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effects and safety of pioglitazone and berberine on the basis of lifestyle intervention to non-alcoholic fatty liver disease patients with impaired glucose regulation or type 2 diabetes mellitus.